New drug may prevent dangerous blood pressure spikes in thyroid surgery

NCT ID NCT07434206

Ongoing Disease control Sponsor: South Egypt Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dexmedetomidine, a sedative, can safely control blood pressure and heart rate during surgery to remove active thyroid tumors. Eighty adults aged 20 to 65 are randomly assigned to receive either dexmedetomidine or the standard drug labetalol. The goal is to see if dexmedetomidine provides smoother blood pressure control without causing dangerous drops afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexmedetomidine (Precedex)
What this could lead to: If it works, this could offer a safer way to manage blood pressure spikes during thyroid tumor surgery, reducing complications.
What could go wrong: This is a mid-stage trial with only 80 participants, so results may not apply to everyone. The drug may not outperform standard treatments and could cause low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Thyroid Neoplasms thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID NEOPLASMS

Contacts and locations

Locations

south Egypt cancer institute

Asyut, 171516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.